[go: up one dir, main page]

AU2001252562A1 - Medicinal compositions for suppressing beta-amyloid production - Google Patents

Medicinal compositions for suppressing beta-amyloid production

Info

Publication number
AU2001252562A1
AU2001252562A1 AU2001252562A AU5256201A AU2001252562A1 AU 2001252562 A1 AU2001252562 A1 AU 2001252562A1 AU 2001252562 A AU2001252562 A AU 2001252562A AU 5256201 A AU5256201 A AU 5256201A AU 2001252562 A1 AU2001252562 A1 AU 2001252562A1
Authority
AU
Australia
Prior art keywords
medicinal compositions
amyloid production
suppressing beta
beta
suppressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001252562A
Inventor
Shunichiro Hachiya
Shigeki Kawabata
Toshiharu Suzuki
Toru Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of AU2001252562A1 publication Critical patent/AU2001252562A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001252562A 2000-04-28 2001-04-25 Medicinal compositions for suppressing beta-amyloid production Abandoned AU2001252562A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000131037 2000-04-28
JP2000-131037 2000-04-28
PCT/JP2001/003555 WO2001082967A1 (en) 2000-04-28 2001-04-25 MEDICINAL COMPOSITIONS FOR SUPPRESSING β-AMYLOID PRODUCTION

Publications (1)

Publication Number Publication Date
AU2001252562A1 true AU2001252562A1 (en) 2001-11-12

Family

ID=18640014

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001252562A Abandoned AU2001252562A1 (en) 2000-04-28 2001-04-25 Medicinal compositions for suppressing beta-amyloid production

Country Status (4)

Country Link
EP (1) EP1277478A4 (en)
JP (1) JP4216503B2 (en)
AU (1) AU2001252562A1 (en)
WO (1) WO2001082967A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399775B2 (en) * 2001-12-27 2008-07-15 Daiichi Pharmaceutical Co., Ltd. β-amyloid protein production/secretion inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116460A1 (en) * 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
GB9311132D0 (en) * 1993-05-28 1993-07-14 Eisai London Res Lab Ltd Control of cell death
ES2196181T3 (en) * 1995-11-01 2003-12-16 Novartis Ag PURINE DERIVATIVES AND PROCESS FOR PREPARATION.
US5672508A (en) * 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
ATE311884T1 (en) * 1997-07-12 2005-12-15 Cancer Rec Tech Ltd CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES
AU735127B2 (en) * 1997-08-07 2001-06-28 Regents Of The University Of California, The Purine inhibitor of protein kinases, G proteins and polymerases
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
AU747705C (en) * 1997-12-13 2004-09-23 Bristol-Myers Squibb Company Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors
EP1042509A1 (en) * 1997-12-24 2000-10-11 The Regents of the University of California Methods of using oligonucleotide arrays to search for new kinase inhibitors
EP1087951B9 (en) * 1998-06-18 2006-09-13 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases

Also Published As

Publication number Publication date
EP1277478A4 (en) 2007-09-26
JPWO2001082967A1 (en) 2004-02-05
WO2001082967A1 (en) 2001-11-08
WO2001082967A8 (en) 2002-05-30
JP4216503B2 (en) 2009-01-28
EP1277478A1 (en) 2003-01-22

Similar Documents

Publication Publication Date Title
AU781269C (en) Pharmaceutical compositions
AU2002313236A1 (en) Medicinal compositions
AU2001250420A1 (en) Pharmaceutical compositions
AU2002222118A1 (en) Pharmaceutical compositions for inhalation
AU3192700A (en) Medicinal compositions
AU2001274307A1 (en) Pharmaceutical compositions
AU2001281887A1 (en) Enamel composition
AU2002302147A1 (en) Pharmaceutical composition
AU2005300A (en) Medicinal compositions
AU3556400A (en) Pharmaceutical compositions
AU2002258221A1 (en) Medicinal composition
AU1887401A (en) Medicinal composition
AU2002214324A1 (en) Medicinal compositions
AU2001262733A1 (en) Medicinal compositions containing propenone derivatives
AU2001290239A1 (en) Medicinal composition
AU2002221115A1 (en) Medicinal compositions having improved absorbability
AU2001225164A1 (en) Compositions with enhanced oral bioavailability
AU2001273919A1 (en) Pharmaceutical compositions
AU6460400A (en) Pharmaceutical compositions
AU2002215114A1 (en) Pharmaceutical compositions for inhalation
AU2001270235A1 (en) Oral compositions
AU6460200A (en) Pharmaceutical compositions
AU4085201A (en) Pharmaceutical composition
AU2001290669A1 (en) Oral compositions
AU6460100A (en) Pharmaceutical compositions